Skip to content

Acadia Pharmaceuticals ACAD Change in receivables

Change in receivables at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$40.39M-15.5%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$474K-96.6%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$205K-103%
Alkermes logo
AlkermesALKS
$23.22M+135%
LQD
Liquidia CorporationLQDA
$20.06M+1,463%

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's change in receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's change in receivables?
Acadia Pharmaceuticals (ACAD) reported change in receivables of -$13.74M in Q1 2026.
How has Acadia Pharmaceuticals's change in receivables changed year-over-year?
Acadia Pharmaceuticals's change in receivables decreased by 781.9% year-over-year, from $2.02M to -$13.74M.
What does change in receivables mean?
Change in total receivables including trade and non-trade receivables.